This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Christos Velentzas, MD; Demitris Carras, MD; John Vassilouthis, MD

JAMA. 1981;245(11):1149-1150.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IT HAS been demonstrated that treatment with bromocriptine mesylate can reduce the size of pituitary prolactinomas.^1,2 The actual mechanism by which this is achieved remains obscure, although bromocriptine has been shown to reduce the mitotic rate of the tumor in rats.³ In man, bromocriptine, an ergot derivative and dopamine agonist, has a potent inhibitory action on prolactin secretion and, in patients with hyperprolactinemia, it lowers serum prolactin levels and restores gonadal function.¹

We treated a patient with a sizeable pituitary prolactinoma with bromocriptine alone. A remarkable reduction of the tumor size was achieved in addition to the reversal of the biochemical features.

Report of a Case

A 20-year-old man was referred to us for further investigation of hypogonadism and occasional diplopia, which occurred on his looking to the left. His medical history revealed that he had not yet reached puberty and libido was absent. Otherwise, his medical . . . [Full Text PDF of this Article]

Author Affiliations
From the Departments of Internal Medicine (Drs Velentzas and Carras), and Neurosurgery (Dr Vassilouthis), 401 Military Hospital, Athens, Greece.

Footnotes
Reprint requests to 8 Alopekis St, Kolonaki, Athens, Greece (Dr Vassilouthis).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?